JAKARTA, Indonesia--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. “Meiji” has announced that it launched the following two products from Santen Pharmaceutical Co., Ltd. “Santen” in Indonesia, based on a working business agreement that Meiji entered in November of 2018 with Santen.
DIQUAS ophthalmic solution 3% (Diquafosol Sodium)
Glaucoma and ocular hypertension treatment
TAFLOTAN ophthalmic solution 0.0015% (Tafluprost)
Based on the working business agreement with Santen, these products will be marketed in Indonesia by Meiji’s affiliated subsidiary, PT. Meiji Indonesian Pharmaceutical Industries “PT. Meiji”. PT. Meiji established a new marketing team specialized on ophthalmic treatments, and Santen will support their marketing activities. Moving forward, PT. Meiji will continue to add more products and expand the product lineup. PT. Meiji and Santen work together to expand market share in Indonesia for ophthalmic products.
Meiji and Santen, through the marketing of ophthalmic treatments in Indonesia, are contributing to the health of the peoples of ASEAN countries.
About Meiji Seika Pharma Co., Ltd
Address: Chuo-ku, Tokyo Japan
President and CEO: Daikichiro Kobayashi
About Santen Pharmaceutical Co., Ltd.
Address: Kita-ku, Osaka Japan
President and CEO: Akira Kurokawa
About PT. Meiji Indonesian Pharmaceutical Industries
Address: Jalan Prof. Dr. Soepomo No. 40, Tebet, Jakarta Selatan, 12870 Indonesia
President Director: Masanobu Sato
Employees: 799, as of March, 2019
Parent Company: Meiji Seika Pharma Co., Ltd.
Scope of Business: Manufacture, sales, and export of medical products and materials
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.